S

Sanofi

Global pharma company; vaccines and R&D

Evidence Synthesis Manager

Full-TimeDeadline 11/28/26
No salary listed
Expert
Bachelor's, MD
Hyderabad, Telangana, India
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • At least 8 years of experience in HEOR within the pharmaceutical industry, a CRO consultancy, or academia.
  • Demonstrate effective communication, organizational, and interpersonal skills.
  • Work effectively as part of multidisciplinary global teams.
  • Work independently under management direction and within functional policies, budgetary guidelines, company values, ethics, and applicable law.
  • Handle multiple projects across different therapeutic areas.
  • Understand the disease environment and the evolution of the market access landscape and its business implications.
  • Have a proven track record working successfully in a project- or matrix-oriented environment.
  • Understand and present complex information clearly to internal and external audiences.
  • Demonstrate team spirit, transversality, multicultural awareness, and ability to drive matrix teams.
  • Apply strong analytical skills to translate clinical and economic information into payer evidence strategies.
  • Understand reimbursement decisions, value drivers, evidence use in decision-making, and impacts on providers, patients, health systems, and other payers.
  • Know methods and principles of health economics and health technology assessment reviews.
  • Hold an advanced degree in life sciences, pharmacy, or a similar discipline, or a medical degree.
  • Have excellent spoken and written English.
Responsibilities
  • Manage assigned Evidence Synthesis projects in the portfolio, planning and generating robust health economics and value-based evidence to maximize global and US value propositions while working with Global HEVA business partners and the Global HEVA Evidence Synthesis lead.
  • Manage and execute quality research projects, economic models, trial design recommendations, and other activities supporting programs and products.
  • Support the planning, design, implementation, and completion of innovative evidence-based research programs aligned with program and product strategies, generating evidence and tools for internal decision-making and external audiences throughout product launch and lifecycle.
  • Identify opportunities to innovate HEVA value identification, evidence generation, and dissemination processes to increase the relevance and impact of evidence and support optimal reimbursement and access decisions.
  • Create complex and specialized strategic content without supervision.
  • Develop and maintain therapeutic-area expertise.
  • Develop and review content created by HEVA associates and coach associates.
  • Develop relationships with internal stakeholders across Medical Affairs, Clinical Development, Commercial, and Market Access; provide feedback to HEVA associates; and work with global HEVA teams across time zones.
  • Manage evidence-generation projects with Global HEVA business partners, including developing research plans for pre-launch, launch, and post-launch evidence for investigational and marketed drugs.
  • Plan evidence generation that may include burden-of-illness studies, epidemiology, literature reviews, meta-analysis, retrospective and prospective observational studies, economic evaluations, and development and analysis of patient-reported outcomes.
  • Provide strategic support to identify individuals and institutions as evidence-generation resources.
  • Work with HEVA product leads to manage and execute research studies supporting the clinical, economic, and humanistic value of products.
  • Lead development of core value dossiers and AMCP dossiers under the strategic direction of Global HEVA business partners.
  • Develop complex HEVA strategic evidence materials and build expertise in HEVA for the assigned therapeutic area.
  • Manage core HEVA strategic evidence-generation processes, templates, and products across the portfolio in alignment with scientific and value messages in core value dossiers, US AMCP dossiers, and other relevant submissions.
  • Ensure adherence to evidence-generation guidelines and other standards applicable to HEVA processes at SBO.
  • Use advanced training-delivery tools and techniques; design action plans based on end-customer feedback and improve course content and delivery.
  • Work with HEVA, RWE, Clinical, Medical Affairs, Marketing, External Affairs, and Market Access teams to identify evidence-generation and dissemination needs and develop assigned deliverables.
  • Coordinate with internal and external teams to prepare customized deliverables and keep assigned project milestones and timelines on track.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...